Fig. 1.
IBD patients on anti-TNFα have fewer T and NK cells and improvement in inflammatory markers. PBMC from patients and control subjects were immunostained and CD2+ cells enumerated by FACS in A. Inflammatory markers, erythrocyte sedimentation rate and c-reactive protein, before (black bars) and after (open bars) anti-TNFα therapy are shown in B. Data represent mean +/− SEM.